Could Anika Therapeutics Inc (NASDAQ:ANIK) Go Up After Its Newest Short Interest Report?

May 16, 2018 - By Jimmy Baldridge

Anika Therapeutics, Inc. (NASDAQ:ANIK) Logo

Investors sentiment decreased to 1.37 in Q4 2017. Its down 0.05, from 1.42 in 2017Q3. It worsened, as 12 investors sold Anika Therapeutics, Inc. shares while 45 reduced holdings. 24 funds opened positions while 54 raised stakes. 12.26 million shares or 0.18% less from 12.29 million shares in 2017Q3 were reported.
Mason Street Advisors Ltd has 3,813 shares. Invesco Limited owns 0% invested in Anika Therapeutics, Inc. (NASDAQ:ANIK) for 53,266 shares. Piermont Capital Management Inc holds 0.68% or 38,284 shares in its portfolio. Citadel Advsr Limited Liability Co holds 0% of its portfolio in Anika Therapeutics, Inc. (NASDAQ:ANIK) for 34,859 shares. Comerica Fincl Bank reported 15,246 shares. Goldman Sachs Gru Incorporated reported 150,643 shares. Tiaa Cref Inv Mgmt Limited Liability Company accumulated 36,001 shares or 0% of the stock. Tower Research Capital Lc (Trc), a New York-based fund reported 220 shares. State Street Corporation owns 378,926 shares. Vanguard, Pennsylvania-based fund reported 834,970 shares. Mutual Of America Llc has 50,467 shares for 0.04% of their portfolio. Sector Pension Investment Board has invested 0% in Anika Therapeutics, Inc. (NASDAQ:ANIK). Bokf Na has invested 0.02% in Anika Therapeutics, Inc. (NASDAQ:ANIK). Bancshares Of Ny Mellon reported 0.01% of its portfolio in Anika Therapeutics, Inc. (NASDAQ:ANIK). Alps Advsrs stated it has 0% of its portfolio in Anika Therapeutics, Inc. (NASDAQ:ANIK).

The stock of Anika Therapeutics Inc (NASDAQ:ANIK) registered an increase of 2.92% in short interest. ANIK’s total short interest was 1.20 million shares in May as published by FINRA. Its up 2.92% from 1.17M shares, reported previously. With 140,800 shares average volume, it will take short sellers 9 days to cover their ANIK’s short positions. The short interest to Anika Therapeutics Inc’s float is 8.36%.

The stock increased 4.82% or $1.84 during the last trading session, reaching $39.99. About 469,468 shares traded or 251.92% up from the average. Anika Therapeutics, Inc. (NASDAQ:ANIK) has risen 15.35% since May 16, 2017 and is uptrending. It has outperformed by 3.80% the S&P500.

Anika Therapeutics, Inc., together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company has market cap of $589.66 million. The firm develops, makes, and commercializes therapeutic products based on its proprietary hyaluronic acid technology. It has a 18.95 P/E ratio. The Company’s orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a woven gauze used as a bone graft wrap; HYALOSS used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment.

Anika Therapeutics, Inc. (NASDAQ:ANIK) Ratings Coverage

Among 3 analysts covering Anika Therapeutics Inc (NASDAQ:ANIK), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Anika Therapeutics Inc had 4 analyst reports since December 28, 2017 according to SRatingsIntel. On Friday, May 4 the stock rating was upgraded by Barrington Research to “Outperform”. The stock has “Overweight” rating by First Analysis on Wednesday, January 24. The firm has “Market Perform” rating given on Friday, February 23 by Barrington Research.

More notable recent Anika Therapeutics, Inc. (NASDAQ:ANIK) news were published by: which released: “Anika to Present at the 2018 Deutsche Bank Health Care Conference on May 8, 2018” on April 24, 2018, also with their article: “Report: Developing Opportunities within AMC Networks, JELD-WEN Holding, Blueprint Medicines, Northwest …” published on May 01, 2018, published: “Mid-Afternoon Market Update: Dow Turns Positive; Anika Therapeutics Shares Fall Following Disappointing Q1 Results” on May 03, 2018. More interesting news about Anika Therapeutics, Inc. (NASDAQ:ANIK) were released by: and their article: “The Week Ahead In Biotech: PDUFA Dates, Clinical Trials, Merck And Pfizer Earnings On Tap” published on April 29, 2018 as well as‘s news article titled: “J&J cost cutting plan may pressure suppliers – Bloomberg” with publication date: April 17, 2018.

Anika Therapeutics, Inc. (NASDAQ:ANIK) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: